# US 2019/0314508 A1 · P53 degradation inducing molecule and pharmaceutical composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314508 A1
- Document ID: US20190314508A1
- Status: Published application
- Kind: A1
- Application number: 16/349,708
- Filed: 2017-11-13
- Published: 2019-10-17
- Earliest claimed: 2016-11-15
- Assignees: Tokyo University of Science Foundation
- Applicants: Tokyo University of Science Foundation
- Inventors: Etsuko MIYAMOTO; Masaaki OZAWA
- Web page: https://patentgrep.com/patent/US20190314508A1

## CPC

- A61K 47/54: the modifying agent being an organic compound
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 237/22: having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated (peptides C07K)
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07K 5/06026: {the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala}
- C07K 5/0808: {the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A p53 degradation inducing molecule which can induce degradation of p53 proteins or p53 composites, and a pharmaceutical composition containing said p53 degradation inducing molecule are provided. This p53 degradation inducing molecule is a conjugate of a p53 affinity molecule which has affinity for p53 proteins or p53 composites, and a proteolysis induction tag which has affinity for protease and which does not inhibit proteolysis of proteins by protease.

## Claims

### Claim 1

A p53 degradation inducing molecule being a conjugate of a p53 affinity molecule that has an affinity with a p53 protein or a p53 complex, and a protein-degradation inducing tag that has an affinity with a protease and does not inhibit degradation of a protein by the protease; and being capable of inducing degradation of the p53 protein or the p53 complex.

### Claim 2 (depends on 1)

The p53 degradation inducing molecule according to claim 1, wherein the p53 degradation inducing molecule is capable of inducing degradation of the p53 protein or the p53 complex in a ubiquitin-independent manner.

### Claim 3 (depends on 1)

The p53 degradation inducing molecule according to claim 1, wherein the protein-degradation inducing tag has a structure where a protease inhibitory activity of a protease inhibitor is inactivated.

### Claim 4 (depends on 1)

The p53 degradation inducing molecule according to claim 1, wherein the protease is a proteasome.

### Claim 5 (depends on 4)

The p53 degradation inducing molecule according to claim 4, wherein the protein-degradation inducing tag has a structure where a proteasome inhibitory activity of a proteasome inhibitor is inactivated.

### Claim 6 (depends on 5)

The p53 degradation inducing molecule according to claim 5, wherein the proteasome inhibitory activity is an inhibitory activity against at least one selected from a caspase-like activity, a trypsin-like activity, and a chymotrypsin-like activity.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising the p53 degradation inducing molecule according to claim 1.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is used for preventing or treating a p53 protein-mediated disease or condition.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the p53 protein-mediated disease or condition is a cancer, cellular senescence, a neurological disease, neuronal cell death, diabetes, or cardiac dysfunction.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, wherein the p53 protein-mediated disease or condition is cellular senescence.
